Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
December 11, 2019 09:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the pricing of an underwritten public offering of 28,000,000...
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
December 10, 2019 16:25 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell shares of its common stock...
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
December 09, 2019 06:30 ET
|
Marinus Pharmaceuticals, Inc.
Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020 European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5...
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
December 07, 2019 00:01 ET
|
Marinus Pharmaceuticals, Inc.
100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone effective regardless of...
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
November 27, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2019 16:00 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
November 06, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a...
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
October 29, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
October 17, 2019 07:30 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 27, 2019 16:05 ET
|
Marinus Pharmaceuticals, Inc.
RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...